Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy

References

• Jacobson C, LaCasce A. How I treat Burkitt lymphoma in adults. Blood. 2014;124:2913–2920.
   PubMed Web of Science ®Google Scholar
• Molyneux EM, Rochford R, Griffin B, et al. Burkitt’s lymphoma. Lancet. 2012;379:1234–1244.
   PubMed Web of Science ®Google Scholar
• Burkitt D. A sarcoma involving the jaws in african children. Br J Surg. 1958;46:218–223.
   PubMed Web of Science ®Google Scholar
• Bouda GC, Traore F, Couitchere L, et al. Advanced Burkitt lymphoma in Sub-Saharan Africa pediatric units: results of the Third Prospective Multicenter Study of the Groupe Franco-Africain d’Oncologie Pediatrique. JGO. 2019;5:1–9.
   Google Scholar
• Painschab MS, Westmoreland KD, Kasonkanji E, et al. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi. Blood Adv. 2019;3:612–620.
   PubMed Web of Science ®Google Scholar
• Gopal S, Gross TG. How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood. 2018;132:254–263.
   PubMed Web of Science ®Google Scholar
• Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107:265–276.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Fallah J, Castillo JJ. Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base. Cancer. 2016;122:2689–2697.
   PubMed Web of Science ®Google Scholar
• NPCR and SEER Incidence – U.S. Cancer Statistics Public Use Database with Puerto Rico, Nov 2018. Submission (2005–2016). United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Released June 2019, based on the November 2018 submission. Available from: www.cdc.gov/cancer/npcr/public-use
   Google Scholar
• Cote TR, Biggar RJ, Rosenberg PS, et al.; The AIDS/Cancer Study Group. Non-Hodgkin’s lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer. 1997;73:645–650.
   PubMed Web of Science ®Google Scholar
• Guech-Ongey M, Simard EP, Anderson WF, et al. AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology. Blood. 2010;116:5600–5604.
   PubMed Web of Science ®Google Scholar
• Hamilton-Dutoit SJ, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. Blood. 1993;82:619–624.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH; World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues (Revised 4th edition). Lyon (France): International Agency for Research on Cancer; 2017.
   Google Scholar
• Zech L, Haglund U, Nilsson K, et al. Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer. 1976;17:47–56.
   PubMed Web of Science ®Google Scholar
• Taub R, Kirsch I, Morton C, et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA. 1982;79:7837–7841.
   PubMed Web of Science ®Google Scholar
• Dalla-Favera R, Bregni M, Erikson J, et al. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA. 1982;79:7824–7827.
   PubMed Web of Science ®Google Scholar
• Grande BM, Gerhard DS, Jiang A, et al. Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133:1313–1324.
   PubMed Web of Science ®Google Scholar
• Evens AM, Danilov A, Jagadeesh D, et al. The evaluation and treatment (Tx) of Burkitt lymphoma (BL) in the modern era: real world (RW) outcomes and prognostication across 26 US Cancer Centers (CC). Blood. 2019;134:397.
   Web of Science ®Google Scholar
• Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595–5610.
   PubMed Web of Science ®Google Scholar
• Lin CY, Loven J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151:56–67.
   PubMed Web of Science ®Google Scholar
• Dang CV. MYC on the path to cancer. Cell. 2012;149:22–35.
   PubMed Web of Science ®Google Scholar
• Calado DP, Sasaki Y, Godinho SA, et al. The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. Nat Immunol. 2012;13:1092–1100.
   PubMed Web of Science ®Google Scholar
• Dominguez-Sola D, Victora GD, Ying CY, et al. The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. Nat Immunol. 2012;13:1083–1091.
   PubMed Web of Science ®Google Scholar
• Basso K, Dalla-Favera R. Germinal centres and B cell lymphomagenesis. Nat Rev Immunol. 2015;15:172–184.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–2330.
   PubMed Web of Science ®Google Scholar
• Ott G, Rosenwald A, Campo E. Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood. 2013;122:3884–3891.
   PubMed Web of Science ®Google Scholar
• Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27:6462–6472.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Nabhan C, Smith SM. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer. 2014;120:3884–3895.
   PubMed Web of Science ®Google Scholar
• Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–2442.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–2430.
   PubMed Web of Science ®Google Scholar
• Victora GD, Dominguez-Sola D, Holmes AB, et al. Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. Blood. 2012;120:2240–2248.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Young RM, Ceribelli M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–120.
   PubMed Web of Science ®Google Scholar
• Richter J, Schlesner M, Hoffmann S, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012; 44:1316–1320.
   PubMed Web of Science ®Google Scholar
• Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012;44:1321–1325.
   PubMed Web of Science ®Google Scholar
• Rohde M, Bonn BR, Zimmermann M, et al.; MMML-MYC-SYS Project. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Munster protocols. Haematologica. 2017;102:1091–1098.
   PubMed Web of Science ®Google Scholar
• Havelange V, Pepermans X, Ameye G, et al. Genetic differences between paediatric and adult Burkitt lymphomas. Br J Haematol. 2016;173:137–144.
   PubMed Web of Science ®Google Scholar
• Bouska A, Bi C, Lone W, et al. Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood. 2017;130:1819–1831.
   PubMed Web of Science ®Google Scholar
• Panea RI, Love CL, Shingleton JR, et al. The whole-genome landscape of Burkitt lymphoma subtypes. Blood. 2019;134:1598–1607.
   PubMed Web of Science ®Google Scholar
• Sander S, Calado DP, Srinivasan L, et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell. 2012;22:167–179.
   PubMed Web of Science ®Google Scholar
• Walter R, Pan KT, Doebele C, et al. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling. Blood. 2017;129:598–608.
   PubMed Web of Science ®Google Scholar
• Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov. 2013;12:229–243.
   PubMed Web of Science ®Google Scholar
• Corso J, Pan KT, Walter R, et al. Elucidation of tonic and activated B-cell receptor signaling in Burkitt’s lymphoma provides insights into regulation of cell survival. Proc Natl Acad Sci Usa. 2016;113:5688–5693.
   PubMed Web of Science ®Google Scholar
• Tomska K, Kurilov R, Lee KS, et al. Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma. Sci Rep. 2018;8:12046.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Ceribelli M, Pittaluga S, et al. Oncogenic mechanisms in Burkitt lymphoma. Cold Spring Harb Perspect Med. 2014;4.
   PubMed Web of Science ®Google Scholar
• Kuttler F, Ame P, Clark H, et al. c-myc box II mutations in Burkitt’s lymphoma-derived alleles reduce cell-transformation activity and lower response to broad apoptotic stimuli. Oncogene. 2001;20:6084–6094.
   PubMed Web of Science ®Google Scholar
• Bahram F, von der Lehr N, Cetinkaya C, et al. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000;95:2104–2110.
   PubMed Web of Science ®Google Scholar
• Hemann MT, Bric A, Teruya-Feldstein J, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807–811.
   PubMed Web of Science ®Google Scholar
• Derenzini E, Mondello P, Erazo T, et al. BET inhibition-induced GSK3beta feedback enhances lymphoma vulnerability to PI3K inhibitors. Cell Rep. 2018;24:2155–2166.
   PubMed Web of Science ®Google Scholar
• Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. JCO. 1996;14:925–934.
   PubMed Web of Science ®Google Scholar
• Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:2248–2260.
   PubMed Web of Science ®Google Scholar
• Noy A, Lee JY, Cesarman E, et al. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015;126:160–166.
   PubMed Web of Science ®Google Scholar
• Lacasce A, Howard O, Li S, et al. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761–767.
   PubMed Web of Science ®Google Scholar
• Evens AM, Carson KR, Kolesar J, et al. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt’s lymphoma. Ann Oncol. 2013;24:3076–3081.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. JCO. 1999;17:2461–2470.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569–1580.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Michon J, et al. The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370–3379.
   PubMed Web of Science ®Google Scholar
• Divine M, Casassus P, Koscielny S, et al. Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol. 2005;16:1928–1935.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt’s lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:2402–2411.
   PubMed Web of Science ®Google Scholar
• Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94:3294–3306.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–3879.
   PubMed Web of Science ®Google Scholar
• Rizzieri DA, Johnson JL, Byrd JC, et al.; the Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014;165:102–111.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt’s lymphoma. N Engl J Med. 2013;369:1915–1925.
   PubMed Web of Science ®Google Scholar
• Roschewski M, Dunleavy K, Abramson JS, et al. Risk-adapted therapy in adults with Burkitt lymphoma: results of NCI 9177, a multicenter prospective phase II study of DA-EPOCH-R. Blood. 2017;130:188.
   Web of Science ®Google Scholar
• Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–3020.
   PubMed Web of Science ®Google Scholar
• Wasterlid T, Brown PN, Hagberg O, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol. 2013;24:1879–1886.
   PubMed Web of Science ®Google Scholar
• Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas. Br J Haematol. 2018;181:495–504.
   PubMed Web of Science ®Google Scholar
• B-cell lymphomas. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), version 6.2019. November 26, 2019. Available from: https://www.nccn.org/professionals/physician_gls/
   Google Scholar
• Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–1111.
   PubMed Web of Science ®Google Scholar
• Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264–1274.
   PubMed Web of Science ®Google Scholar
• Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94:1492–1499.
   PubMed Web of Science ®Google Scholar
• Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-associated Burkitt lymphoma: good efficacy and tolerance of intensive chemotherapy including CODOX-M/IVAC with or without rituximab in the HAART Era. Adv Hematol. 2012; 2012:1–9.
   Google Scholar
• Short NJ, Kantarjian HM, Ko H, et al. Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma. Am J Hematol. 2017;92:E114–E117.
   PubMed Web of Science ®Google Scholar
• Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt’s lymphoma: a retrospective analysis. Ann Oncol. 2011;22:1859–1864.
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113:117–125.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Garcia O, Grande C, et al. Dose-intensive chemotherapy including rituximab in Burkitt’s leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab). Cancer. 2013;119:1660–1668.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome. Blood. 2006;108:2736.
   PubMedGoogle Scholar
• Oosten LEM, Chamuleau MED, Thielen FW, et al. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol. 2018;97:255–266.
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Winer ES, Olszewski AJ. Population-based prognostic factors for survival in patients with Burkitt lymphoma: an analysis from the Surveillance, Epidemiology, and End Results database. Cancer. 2013;119:3672–3679.
   PubMed Web of Science ®Google Scholar
• Jakobsen LH, Ellin F, Smeland KB, et al. Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J Haematol. 2020.
   PubMed Web of Science ®Google Scholar
• Nkrumah FK, Perkins IV. Relapse in Burkitt’s lymphoma. Int J Cancer. 1976;17:455–460.
   PubMed Web of Science ®Google Scholar
• Sariban E, Edwards B, Janus C, et al. Central nervous system involvement in American Burkitt’s lymphoma. JCO. 1983;1:677–681.
   PubMed Web of Science ®Google Scholar
• Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL. Ann Oncol. 2007;18:149–157).
   PubMed Web of Science ®Google Scholar
• Zayac A, Evens AM, Stadnik A, et al. Outcomes of patients with newly-diagnosed Burkitt lymphoma (BL) and central nervous system (CNS) involvement treated in the modern era: a multi-institutional real-world analysis. Blood. 2019;134:402.
   Web of Science ®Google Scholar
• Ollila TA, Olszewski AJ. Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol. 2018;19:38.
   PubMed Web of Science ®Google Scholar
• Decker DP, Egan PC, Zayac AS, et al. Treatment strategies and risk of central nervous system recurrence in high-grade B-cell and Burkitt lymphoma. Leuk Lymphoma. 2020;61:198–201.
   PubMed Web of Science ®Google Scholar
• Alderuccio JP, Lossos IS. DA-EPOCH-R for adult Burkitt’s lymphoma: pros and cons. JOP. 2018;14:676–678.
   PubMedGoogle Scholar
• Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt’s and Burkitt-like non-Hodgkin’s lymphoma–outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. JCO. 1996;14:2465–2472.
   PubMed Web of Science ®Google Scholar
• Maramattom LV, Hari PN, Burns LJ, et al. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013;19:173–179.
   PubMed Web of Science ®Google Scholar
• Center for International Blood & Marrow Transplant Research. Transplant Activity Report. 2020 [accessed 2020 Jan 12]. Available from: https://bloodstemcell.hrsa.gov/data/donation-and-transplantation-statistics/transplant-activity-report
   Google Scholar
• Tanaka Y, Momose S, Tabayashi T, et al. Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas. Cancer Sci. 2020;111:749–759.
   PubMed Web of Science ®Google Scholar
• Ippolito T, Gu JJ, Tang G, et al. Targeting BET bromodomains in pre-clinical models of Burkitt lymphoma. Blood. 2016;128:5381–5381.
   Google Scholar
• Ippolito T, Mavis C, Gu J, et al. Omipalisib (GSK458), a dual an-PI3K/mTOR inhibitor, exhibits in vitro and in vivo activity in chemotherapy-sensitive and -resistant models of Burkitt lymphoma. Blood. 2018;132:2951–2951.
   Web of Science ®Google Scholar
• Bhatti M, Ippolito T, Mavis C, et al. Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. Oncotarget. 2018;9:21820–21830.
   PubMedGoogle Scholar
• Dickinson M, Kamdar M, Huntly BJP, et al. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open label single agent study in subjects with non-Hodgkin’s lymphoma (NHL). Blood. 2018;132:1682–1682.
   Web of Science ®Google Scholar
• Daly T, Ippolito T, Gu JJ, et al. MCL-1 inhibition by the selective MCL-1 inhibitor AMG-176 induces in vitro activity against Burkitt lymphoma cell lines and synergistically enhances the cytotoxic effect of chemotherapy and BH3 mimetics. Blood. 2019;134:5303–5303.
   Google Scholar
• Pardee TS, Lee K, Luddy J, et al. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20:5255–5264.
   PubMed Web of Science ®Google Scholar
• Noy A, Pardee TS, Nikolaenko L, et al. A phase II clinical trial of Cpi-613 (devimistat) in patients with relapsed or refractory Burkitt lymphoma/leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2and/or BCL6. Blood. 2019;134:4087–4087.
   Google Scholar
• Dunleavy K. Approach to the diagnosis and treatment of adult Burkitt’s lymphoma. JOP. 2018;14:665–671.
   PubMedGoogle Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Avigdor A, Shouval R, Jacoby E, et al. CAR T cells induce a complete response in refractory Burkitt Lymphoma. Bone Marrow Transplant. 2018;53:1583–1585.
   PubMed Web of Science ®Google Scholar
• Riedell PA, Walling C, Nastoupil LJ, et al. A multicenter retrospective analysis of clinical outcomes, toxicities, and patterns of use in institutions utilizing commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B-cell lymphomas. Blood. 2019;134:1599–1599.
   Web of Science ®Google Scholar
• Zhang W, Hu B, Jing L, et al. Early response observed in pediatric patients with refractory/relapsed B-cell non-Hodgkin lymphoma treated with sequential chimeric antigen receptor T cells. Blood. 2019;134:1945–1945.
   Google Scholar
• Wang N, Hu X, Cao W, et al. Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies. Blood. 2020;135:17–27.
   PubMed Web of Science ®Google Scholar
• Feldmann A, Koristka S, Arndt C, et al. Development of novel anti-CD10 target modules for redirection of universal CAR T cells against CD10-positive malignancies. Blood. 2019;134:5612–5612.
   Google Scholar
• Goodridge JP, Mahmood S, Zhu H, et al. FT596: translation of first-of-kind multi-antigen targeted off-the-shelf CAR-NK cell with engineered persistence for the treatment of B cell malignancies. Blood. 2019;134:301–301.
   Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376:836–847.
   PubMed Web of Science ®Google Scholar
• Duell J, Zugmaier G, Eisele F, et al. Treatment of R/R Burkitt lymphoma with blinatumomab is feasible and induced a long lasting complete remission. HemaSphere. 2019; 3:816–817.
   Google Scholar
• Sokol KA, Barlogie B, Steinberg A. Blinatumumab as a bridge to transplant in ALL and the first reported use in myeloma: successes in reaching transplant but with rapid relapse. The Mount Sinai Hospital’s Institutional Experience. Biol Blood Marrow Transplant. 2017;23:S164.
   Web of Science ®Google Scholar
• Poh C, Frankel P, Ruel C, et al. Blinatumomab/lenalidomide in relapsed/refractory non-Hodgkin’s lymphoma: a phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 2019;134:760–760.
   Web of Science ®Google Scholar
• Schuster SJ, Bartlett NL, Assouline S, et al. Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood. 2019;134:6–6.
   PubMed Web of Science ®Google Scholar
• Hutchings M, Ahmadi T, Gupta M, et al. First-in-human, phase 1/2 trial to assess the safety and clinical activity of subcutaneous GEN3013 (DuoBody®-CD3 × CD20) in B-cell non-Hodgkin lymphomas. Blood. 2019;134:758–758.
   Web of Science ®Google Scholar